Consider switching to another disease-modifying therapy when unacceptable disease activity occurs in relapsing multip) sclerosis

摘要

Several disease-modifying therapies with distinct mechanisms of action are currently approved for the treatment of relapsing forms of multiple sclerosis. Switching to treatment with a different disease-modifying agent is a common approach when a patient experiences unacceptable breakthrough disease activity. Several practical points and suggestions for switching therapy in such patients are proposed.